<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955119</url>
  </required_header>
  <id_info>
    <org_study_id>dr.jingxiang003</org_study_id>
    <nct_id>NCT04955119</nct_id>
  </id_info>
  <brief_title>Fusion Imaging Contrast-enhanced Ultrasound LI-RADS</brief_title>
  <official_title>Fusion Imaging Contrast-enhanced Ultrasound LI-RADS in Patients With High-risk Hepatocellular Carcinoma With Focal Liver Lesions Invisible on Conventional Ultrasound: a Multi-center Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Third Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Third Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CEUS LI-RASD apply to lesion visible at precontrast ultrasound but not the lesion invisible.&#xD;
      Fusion imaging can use to invisible lesions at precontrast ultrasound in clinical practice.&#xD;
      Thus, our aim is to explore the application value of CEUS LI-RADS in contrast-enhanced fusion&#xD;
      imaging for focal liver lesions that are not visible on conventional ultrasound in high-risk&#xD;
      patients with hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive predictive value</measure>
    <time_frame>6 months</time_frame>
    <description>The positive predictive value = HCC in LR-5 /all lesions in LR-5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The sensitivity and specificity of CEUS LR-5</measure>
    <time_frame>6 months</time_frame>
    <description>The sensitivity and specificity are calculated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Fusion imaging contrast-enhanced ultrasound LI-RADS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fusion imaging contrast-enhanced ultrasound will be performed in patients with invisible lesion at conventional ultrasound.&#xD;
Drug: SonoVue</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fusion imaging contrast-enhanced ultrasound</intervention_name>
    <description>Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.&#xD;
Drug: SonoVue</description>
    <arm_group_label>Fusion imaging contrast-enhanced ultrasound LI-RADS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients at risk for HCC(Cirrhosis or Chronic hepatitis B viral infection or Current or&#xD;
        prior HCC) Suspicious lesions detected by CECT/MRI but not visible on conventional&#xD;
        ultrasound and US-CECT/MRI fusion imaging Patients sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients without risk of HCC(With cirrhosis due to congenital hepatic fibrosis or With&#xD;
        cirrhosis due to a vascular disorder such as hereditary hemorrhagic telangiectasia,&#xD;
        Budd-Chiari syndrome, chronic portal vein occlusion, cardiac congestion, or diffuse nodular&#xD;
        regenerative hyperplasia) Patients without a successful registration or lesions can be seen&#xD;
        on conventional ultrasound after successful registration Pregnancy or lactation Patients&#xD;
        with pretreat lesion Patients don't sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiang Jing, MD</last_name>
    <phone>02284112323</phone>
    <phone_ext>+86</phone_ext>
    <email>dr.jingxiang@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yan Zhou, MD</last_name>
    <phone>02284118101</phone>
    <phone_ext>+86</phone_ext>
    <email>zhouyan2626@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300170</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 3, 2021</study_first_submitted>
  <study_first_submitted_qc>July 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 3, 2021</last_update_submitted>
  <last_update_submitted_qc>July 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

